New Dupixent ® (dupilumab) data highlight its clinical and real-world impact across dermatological, respiratory and gastrointestinal diseases, including analyses of food allergy sensitization in ...

The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending dupilumab as an ...

An indirect treatment comparison shows that dupilumab and tezepelumab yield broadly similar clinical benefits in patients ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab is approved for atopic dermatitis in children aged 6 months and older. Patients on dupilumab did not ...

A new study published in the journal of Pediatric Dermatology revealed that treatment with dupilumab achieved effective ...

Nearly 30 data presentations at AAD and ESPD highlight the impact of Dupixent on disease measures including rapid itch relief and sustained improvement in disease severity, as well as quality of life ...

BOSTON -- Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) whose symptoms were uncontrolled with H1-antihistamine therapy.

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms of moderate-to-severe atopic dermatitis (eczema) in young children whether ...

Please provide your email address to receive an email when new articles are posted on . Incidence rates for cancers included 12.88 for the exposed group and 15.04 for the unexposed group. Adjusting ...

Compared with dupilumab, a significantly higher proportion of patients treated with upadacitinib achieved both EASI 90 and WP-NRS 0/1 at week 16. Among patients with moderate to severe atopic ...

These improvements — as measured by a significantly lower annualized rate of acute exacerbations, significantly better lung function and quality of life, and significantly less severe symptoms than ...